Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IDELALISIB Cause Progressive multifocal leukoencephalopathy? 41 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 41 reports of Progressive multifocal leukoencephalopathy have been filed in association with IDELALISIB (Zydelig). This represents 0.6% of all adverse event reports for IDELALISIB.

41
Reports of Progressive multifocal leukoencephalopathy with IDELALISIB
0.6%
of all IDELALISIB reports
27
Deaths
15
Hospitalizations

How Dangerous Is Progressive multifocal leukoencephalopathy From IDELALISIB?

Of the 41 reports, 27 (65.9%) resulted in death, 15 (36.6%) required hospitalization, and 2 (4.9%) were considered life-threatening.

Is Progressive multifocal leukoencephalopathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IDELALISIB. However, 41 reports have been filed with the FAERS database.

What Other Side Effects Does IDELALISIB Cause?

Disease progression (1,204) Death (779) Diarrhoea (752) Off label use (548) Pneumonia (426) Pyrexia (371) Drug ineffective (294) Fatigue (284) Dehydration (242) Dyspnoea (206)

What Other Drugs Cause Progressive multifocal leukoencephalopathy?

NATALIZUMAB (1,668) RITUXIMAB (1,647) CYCLOPHOSPHAMIDE (782) PREDNISONE (606) PREDNISOLONE (439) TACROLIMUS (438) METHOTREXATE (428) DOXORUBICIN (421) MYCOPHENOLATE MOFETIL (414) VINCRISTINE (376)

Which IDELALISIB Alternatives Have Lower Progressive multifocal leukoencephalopathy Risk?

IDELALISIB vs IDURSULFASE IDELALISIB vs IFOSFAMIDE IDELALISIB vs IGURATIMOD IDELALISIB vs ILOPERIDONE IDELALISIB vs ILOPROST

Related Pages

IDELALISIB Full Profile All Progressive multifocal leukoencephalopathy Reports All Drugs Causing Progressive multifocal leukoencephalopathy IDELALISIB Demographics